Uscom LimitedASX: UCM

Preliminary and Annual Report to shareholders

· Issued by Uscom Limited

Filed with ASX · · 63 pages · English

Record growth – Total revenue up 44%, Cash receipts up 94%, Thor Laboratories acquired, global structure established, two new device series for market in 2017, CIIC agreement targeting $65m over 5 years. SYDNEY, Australia, Wednesday 17th August 2016: Uscom Limited (ASX code: UCM) (the Company or Uscom), a revenue stage, cardiovascular medical devices company, today released to market its appendix

Uscom Limited on 6ix

Earlier from Uscom

Later from Uscom

All Uscom news releases